Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 2

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 2
---
 to the securities described in this Proxy Statement/Prospectus has been filed with the Securities and Exchange Commission. These securities may not be issued until such registration statement becomes effective. This Proxy Statement/Prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction in which such offer or solicitation would be unlawful.

PRELIMINARY—SUBJECT TO COMPLETION—DATED MARCH 6, 2025 MERGER PROPOSED—YOUR VOTE IS IMPORTANT Dear Enfusion, Inc. Stockholder: On January 10, 2025, Enfusion, Inc. (“ Enfusion”), Clearwater Analytics Holdings, Inc. (“ Clearwater”), Enfusion Ltd. LLC, a subsidiary of Enfusion (“ Enfusion OpCo”), Poseidon Acquirer, Inc., a wholly-owned subsidiary of Clearwater (“ Acquirer”), Poseidon Merger Sub I, Inc., a wholly-owned subsidiary of Clearwater (“ Merger Sub”), and Poseidon Merger Sub II, LLC, an indirect subsidiary of Clearwater (“ Merger Sub II”), entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “ Merger Agreement”). Pursuant to the terms of the Merger Agreement, (i) Merger Sub II will merge with and into Enfusion OpCo (the “ LLC Merger”), with Enfusion OpCo surviving the LLC Merger as an indirect subsidiary of Clearwater, (ii) Merger Sub will merge with and into Enfusion (the “ Merger”), with Enfusion surviving the Merger as a direct, wholly-owned subsidiary of Clearwater (the “ Surviving Corporation”), and (iii) subject to satisfaction of certain conditions in the Merger Agreement, the Surviving Corporation will merge with and into Acquirer (the “ Second Merger” and, together with the Merger, the “ Corporate Mergers” and the Corporate Mergers, together with the LLC Merger, the “ Mergers”), with Acquirer surviving the Second Merger as a direct, wholly-owned subsidiary of Clearwater. If the Second Merger does not occur, references to the “Mergers” herein will mean the Merger and the LLC Merger. Upon the terms and subject to the conditions set forth in the Merger Agreement, (i) at the effective time of the Merger (the “ Effective Time”), each (x) share of Class A common stock of Enfusion, par value $